CN108309954A - A kind of the lecithin aliphatic radical reversed hexagonal liquid crystal medicament and preparation method of tea polyphenols - Google Patents

A kind of the lecithin aliphatic radical reversed hexagonal liquid crystal medicament and preparation method of tea polyphenols Download PDF

Info

Publication number
CN108309954A
CN108309954A CN201810124148.4A CN201810124148A CN108309954A CN 108309954 A CN108309954 A CN 108309954A CN 201810124148 A CN201810124148 A CN 201810124148A CN 108309954 A CN108309954 A CN 108309954A
Authority
CN
China
Prior art keywords
lecithin
tea polyphenols
liquid crystal
water
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810124148.4A
Other languages
Chinese (zh)
Inventor
王仲妮
李振
李学鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Normal University
Original Assignee
Shandong Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Normal University filed Critical Shandong Normal University
Priority to CN201810124148.4A priority Critical patent/CN108309954A/en
Publication of CN108309954A publication Critical patent/CN108309954A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This application involves the lecithin aliphatic radical reversed hexagonal liquid crystal medicament and preparation method of a kind of tea polyphenols, tea polyphenols have been encapsulated in the liquid crystal formed by lecithin, oleic acid, PEG 400 and water.Fixation surface active agent content and water content respectively, are configured with 5 HIILiquid crystalline sample.In order to compare the property and performance difference after different phase load medicine, a sample spot is had chosen in non-hexagonal phase region.The phase of liquid crystal is characterized by petrographic microscope and small angle X ray scattering (SAXS).With the increase of oil phase content, HIIPhase system fat water termination layer becomes fine and close.Fourier transform infrared spectroscopy (FTIR) shows the formation of intermolecular hydrogen bonding and high oil content is conducive to the formation of hydrogen bond, this makes the structure of sample more stablize.The extracorporeal releasing experiment of tea polyphenols, which shows LCD vector, has tea polyphenols ideal slow release effect, and the release of drug known to First order dynamic model fitting belongs to concentration diffusion control.

Description

A kind of the lecithin aliphatic radical reversed hexagonal liquid crystal medicament and preparation method of tea polyphenols
Technical field
The present invention relates to pharmaceutical formulation techniques fields, and in particular to a kind of lecithin aliphatic radical reversed hexagonal liquid crystal medicine of tea polyphenols The preparation method of agent.
Background technology
Tea polyphenols are the general names for the polyhydroxyl class compound extracted from tealeaves, have anti-oxidant, anticancer, antibacterial, Inhibit angiocardiopathy, the various actives function such as radiation protection.It causes people in fields such as drug, foods and cosmetics at present Extensive concern and research interest.Catechin is the main component in Green Tea Polyphenols, accounts about 60-80%.However, tea polyphenols It is unstable, it is oxidized easily degradation, it is sensitive to light and alkaline solution, and absorptivity in human body is very low.Tea polyphenols take orally Bioavilability is very low, typically less than 2-5%.Such issues that in order to solve, there are mainly two types of existing methods, first, to molecule Certain positions of structure are acylated or are esterified, but modifying process is complicated and phenolic hydroxyl group can be caused to lose, and thereby reduces biology Activity.Second is that carrier appropriate is selected to encapsulate it.Its good stability can be kept while can to tea polyphenols encapsulating Play the role of being sustained and limiting its unnecessary toxicity.In field of food, encapsulating can increase the concentration of Active Ingredient in Food, It can also avoid its interaction between food composition.By the end of currently, the encapsulating for tea polyphenols relates generally to nanometer Carrier, including micella, liposome, solid fat nanoparticle, lotion, multiple emulsion, biopolymer nano-particle etc..Although these Carrier is with the obvious advantage, but still there is also self aggregation and phenomenon of burst release for nano-carrier.In recent years, Supramolecular self assembly is formed Lysotropic liquid crystal plays considerable effect in drug delivery field.Lysotropic liquid crystal is not only present in cell membrane, Er Qie It is also distributed in the organ of life entity.Lysotropic liquid crystal, especially reversed hexagonal liquid crystal (HII) as tea polyphenols carrier in text It is also rarely reported in offering.
Lecithin also known as phosphatidyl choline, in soybean, content is considerable in vegetable seed and yolk, and extraction process is ripe.It is A kind of amphoteric surfactant possesses polar group and two hydrocarbon chains.It is the important component of human-body biological film, to maintaining The physiological activity of biomembrane and the eubolism of body play a crucial role, and have good biocompatibility.Lecithin biology work( It for preventing and improving cardiovascular and cerebrovascular disease, brain tonic and intelligence development, prevent fatty liver and hepatic sclerosis, beautification skin, can play non-comprehensively Normal important role.Lecithin in human body percentage of liveweight 1% or so, but account for the 30% of brain weight in the brain, and The 70-80% of its dry weight is more accounted in brain cell.Lecithin concentration is present in brain and nervous system, and blood circulation system is immunized The vitals such as system and the heart, liver, lung, kidney.
Oleic acid is a kind of unsaturated fatty acid, is present in animal and plant fat in the form of glyceride, is dissolved in and penetrates into table Skin and internal layer have the effect of supplement missing sebum and nourishes rough skin.In addition, new old generation of the oleic acid in softening blood vessel and humans and animals It also plays an important role during thanking.Contain double bond in oleic acid, imparts its certain oxidation resistance.But human body itself closes At oleic acid cannot meet the needs, need to obtain from food.Polyethylene glycol 400 is a kind of water-soluble polymer of low pole, It is used for many oral drugs often as the auxiliary material of less toxic low irritant and indissoluble injects the preparation of drug；Simultaneously because it is strong Big solubilising power can increase the stability of enzyme in body and promote the bioconversion of indissoluble substance in aqueous solution.Poly- second two Alcohol series of products can be used for medicament.The lower polyethylene glycol of relative molecular weight can be used as solvent, cosolvent, O/W types emulsifier and Stabilizer also serves as water-soluble ointment base and suppository base for making flocculant, emulsion, injection.Relative molecular weight is high Solid waxy polyethylene glycol be usually used in increasing the viscosity of low-molecular-weight liquid PEG and at solidity, and compensation other drugs；It is right The drug that Yu Shuizhong is not readily dissolved, this product can make the carrier of solid dispersion and disperse purpose to reach solid.
Invention content
For the above-mentioned prior art the problem of, it is an object of the present invention to provide a kind of lecithin of tea polyphenols Base reversed hexagonal liquid crystal medicament.
In order to solve the above technical problems, the technical scheme is that：
A kind of lecithin aliphatic radical reversed hexagonal liquid crystal medicament of tea polyphenols is by tea polyphenols (TP), lecithin (SL), oleic acid (OA), PEG 400 and H2O is formed.Each section forms：The mass ratio of tea polyphenols in a medicament is 1%；Remaining as carrier；Lecithin, Oleic acid, PEG 400 and H2O forms carrier；Lecithin is 49.5-70 parts in carrier, and oleic acid is 2-11 parts, and PEG 400 is 2-11 Part and H2O is 9-47.5 parts.
Surfactant is lecithin；
Oil phase is oleic acid and PEG 400；
The mass ratio of oleic acid and PEG 400 are 5 in the oil phase:5.
It is a further object to provide the preparation methods of the lecithin aliphatic radical reversed hexagonal liquid crystal medicament of tea polyphenols.
A kind of preparation method of the lecithin aliphatic radical reversed hexagonal liquid crystal medicament of tea polyphenols：
1, oleic acid and PEG 400 are mixed and is added with plug with certain mass ratio as oil phase, lecithin and oil phase In colorimetric cylinder, mixing is sufficiently stirred in the water-bath of certain temperature；
2, tea polyphenols are added in the mixture obtained to step 1 and redistilled water is stirred evenly and is centrifuged repeatedly to drive away Bubble；
3, the colorimetric cylinder that step 2 obtains is stood in water bath with thermostatic control and obtains medicament sample.
Preferably, the mass ratio of lecithin and oil phase is 61 in the step 1)：21~77：5.
Preferably, the temperature of water-bath is 60-70 DEG C in the step 1).
Preferably, the ratio of redistilled water and lecithin is 49 in the step 2)：47.5~69：9.
Preferably, the temperature of the water-bath in the step 3 is 37 ± 0.1 DEG C.
Preferably, the time that reaching in the step 3 balances each other is more than or equal to one week.
Beneficial effects of the present invention：
1) tea polyphenols are encapsulated in carrier liquid crystal by this, can not only improve the stability of drug itself, and protection drug is lived Property, and its trap in vivo can be increased.
2) tea polyphenols have slow release effect, and length of holding time, the stickiness of liquid crystal compare under the package of pharmaceutical carrier Greatly, residence time of the drug in gastrointestinal tract can be increased, and then cause absorptivity of the tea polyphenols under controlled release state than burst release Height under state.
Description of the drawings
The accompanying drawings which form a part of this application are used for providing further understanding of the present application, and the application's shows Meaning property embodiment and its explanation do not constitute the improper restriction to the application for explaining the application.
System SL/OA/PEG 400/H when Fig. 1 is 37 DEG C2The pseudoternary phase diagram of O (OA/PEG 400=5/5)
System SL/OA/PEG 400/H when Fig. 2 is 37 DEG C2The polarisation line of O (OA/PEG 400=5/5) typical liquid crystal sample Manage photo
The SAXS spectrograms of typical liquid crystal sample when Fig. 3 is 37 DEG C
Fig. 4 is tea polyphenols (TP) and carries the ATR-FTIR spectrograms of medicine liquid crystalline sample
Fig. 5 be 37 DEG C when liquid crystal in tea polyphenols release profiles.Correspond to first order kinetics by the solid line of each point Fitting
Specific implementation mode
It is noted that following detailed description is all illustrative, it is intended to provide further instruction to the application.Unless another It indicates, all technical and scientific terms used herein has usual with the application person of an ordinary skill in the technical field The identical meanings of understanding.
It should be noted that term used herein above is merely to describe specific implementation mode, and be not intended to restricted root According to the illustrative embodiments of the application.As used herein, unless the context clearly indicates otherwise, otherwise singulative It is also intended to include plural form, additionally, it should be understood that, when in the present specification using term "comprising" and/or " packet Include " when, indicate existing characteristics, step, operation, device, component and/or combination thereof.
Lecithin (SL) is bought from Alfa Aesar Company；Oleic acid (OA, analysis are pure) and PEG 400 (chemistry is pure), It is provided by Chinese traditional Chinese medicines chemical reagent Co., Ltd.Tea polyphenols are bought from the careless plant Trade Co., Ltd. of Yicheng hundred, bag filter (1000Da) is bought from Beijing Suo Laibao Science and Technology Ltd, and water is redistilled water.All drugs are not located further before Reason.
The determination of phasor
First by oleic acid and PEG 400 with mass ratio 5:5 are uniformly mixed as oil phase, according to lecithin and oil phase (10:0→ 0:10) mass ratio weighs in the colorimetric cylinder with plug, and mixing is sufficiently stirred in 60-70 DEG C of water-bath.Then to equipped with Redistilled water is added dropwise in the colorimetric cylinder of lecithin and oil mixture, stirs and evenly mixs and is centrifuged repeatedly to drive bubble away. Finally water-bath standing is balanced each other with reaching at 37 ± 0.1 DEG C, and sample extends equilibration time close at phase boundray, is seen by estimating Phase-state change and the appearance of sample are examined and recorded, determine the phase behavior of system and draws phasor.The liquid crystal sample configured according to phasor Product need at least to balance before test one week to ensure to be formed complete liquid crystal structure.
It will be seen from figure 1 that occurring two mesophase range in the pseudoternary phase diagram of the system, in the lower phase region of water content Sample is sticky, and reversed hexagonal is tentatively predicated by the polarization texture of marble-like.Water content is changed to from 10wt% in the phase region 19wt% is capable of the oil phase of solubilising 39wt%.Sample is reduced compared to another phase region viscosity in the phase region of water content higher position, Transparency reduces, like g., jelly-like but elastic relatively low, soft texture.Between the phase region appears in 38-54wt% water contents, solubilising The oil phase of 8wt%.
With reference to embodiment, the present invention is further described
Embodiment 1
By 6.9g lecithin, 0.25g oleic acid and 0.25g PEG400 are placed in the colorimetric cylinder with plug, at 60-70 DEG C Mixing is sufficiently stirred in water-bath.Then 0.1g tea polyphenols and 2.5g redistilled waters are successively added into the mixture, stirring is mixed It is even and be centrifuged repeatedly to drive bubble away.Balance will be stood in water bath with thermostatic control of the colorimetric cylinder at 37 DEG C one week up to required sample Product.It is denoted as F1.
Embodiment 2
By 6.9g lecithin, 0.65g oleic acid and 0.65g PEG400 are placed in the colorimetric cylinder with plug, at 60-70 DEG C Mixing is sufficiently stirred in water-bath.Then 0.1g tea polyphenols and 1.7g redistilled waters are successively added into the mixture, stirring is mixed It is even and be centrifuged repeatedly to drive bubble away.Balance will be stood in water bath with thermostatic control of the colorimetric cylinder at 37 DEG C one week up to required sample Product.It is denoted as F2.
Embodiment 3
By 6.9g lecithin, 1.05g oleic acid and 1.05g PEG400 are placed in the colorimetric cylinder with plug, at 60-70 DEG C Mixing is sufficiently stirred in water-bath.Then 0.1g tea polyphenols and 0.9g redistilled waters are successively added into the mixture, stirring is mixed It is even and be centrifuged repeatedly to drive bubble away.Balance will be stood in water bath with thermostatic control of the colorimetric cylinder at 37 DEG C one week up to required sample Product.It is denoted as F3.
Embodiment 4
By 6.1g lecithin, 1.05g oleic acid and 1.05g PEG400 are placed in the colorimetric cylinder with plug, at 60-70 DEG C Mixing is sufficiently stirred in water-bath.Then 0.1g tea polyphenols and 1.7g redistilled waters are successively added into the mixture, stirring is mixed It is even and be centrifuged repeatedly to drive bubble away.Balance will be stood in water bath with thermostatic control of the colorimetric cylinder at 37 DEG C one week up to required sample Product.It is denoted as F4.
Embodiment 5
By 7.7g lecithin, 0.25g oleic acid and 0.25g PEG400 are placed in the colorimetric cylinder with plug, at 60-70 DEG C Mixing is sufficiently stirred in water-bath.Then 0.1g tea polyphenols and 1.7g redistilled waters are successively added into the mixture, stirring is mixed It is even and be centrifuged repeatedly to drive bubble away.Balance will be stood in water bath with thermostatic control of the colorimetric cylinder at 37 DEG C one week up to required sample Product.It is denoted as F5.
Embodiment 6
By 4.8g lecithin, 0.175g oleic acid and 0.175g PEG400 are placed in the colorimetric cylinder with plug, at 60-70 DEG C Water-bath in be sufficiently stirred mixing.Then 0.1g tea polyphenols and 4.75g redistilled waters are successively added into the mixture, stir Mixing is simultaneously centrifuged repeatedly to drive bubble away.Balance will be stood in water bath with thermostatic control of the colorimetric cylinder at 37 DEG C one week up to required sample Product.It is denoted as F6.
The fit indices of composition and SAXS characteristic parameters and the tea polyphenols release of 1. typical liquid crystal sample of table.
Sample spot in table 1 be chosen in the mesophase range of oil phase and water phase the sample spots of different variables to tea polyphenols into Row encapsulating.
The measurement of polarization texture
Using the polarization texture of BK-POL type polarized light microscope observing liquid crystalline samples, lamella liquid crystal is coated on glass slide, Upper coverslip is gently pressed, is placed on microscopical objective table and is observed.It is obtained by CCD camera and corresponding computer software inclined Radiograph.
Small angle X ray scattering (SAXS)
Using SAXSess high throughput small angle X ray scattering instrument (Anton-Paar, Austria) liquid is determined at 37 DEG C The spacing of lattice of brilliant sample, the light source of X-ray are copper targets, wavelength 0.154nm, operation voltage and current be respectively 40kV and The distance of 50mA, sample to detector are 264.5mm.Test needs under vacuum to prevent air scattering.It is scattered by SAXS The relative position at peak determines the structure type of lysotropic liquid crystal.
Attenuated total reflection Fourier transform infrared spectrometry (ATR-FTIR)
Liquid crystal group is measured using AlphaT types Fourier Transform Infrared Spectrometer (Bruker Optik GmbH, Germany) The chemical interaction of functional group after dividing variation and introducing.Wave-length coverage is set as 4000cm-1-400cm-1Spectra resolution rate is set It is set to 4cm-1, frequency is set as 50 and is scanned at room temperature to sample.The liquid crystalline sample of soya bean size is equably coated in prism crystalline substance On body.Every time after test, with alcohol and distilled water cleaning down crystal.
Extracorporeal releasing experiment
Extracorporeal releasing experiment of the tea polyphenols in liquid crystal is carried out at 37 DEG C of physiological temp using the method for dialysis.With The phosphate buffer (pH=6.8) of 50mmol simulates small intestine condition.It takes 0.3g to carry liquid crystalline substance in bag filter, bag filter is soaked Not in 50mL dialyzates, it is stirred with constant appropriate speed.At regular intervals, 3.5mL dissolution mediums are taken out, simultaneously The fresh dissolution medium of same volume is added into medium.Pass through ultraviolet specrophotometer (X-3, the limited public affairs of Shanghai member analyzer device Department) absorbance of tea polyphenols is measured under the wavelength of 298nm and then the burst size of drug is obtained by calculation.
F as shown in Figure 21→F5Sample all shows the polarization texture of marble-like, and change of component influences the variation of texture Less.Sample F6Polarization texture in there is oil stripping, have fraction zone-texture fuzzy, thus it is speculated that be mixed phase.
From the figure 3, it may be seen that in terms of scattering curve, there is level-one, two level and three-level scattering peak in these samples.Sample F1→F5 Three scattering peaks can be indexed as 100,110,200, corresponding typical hexagonal phase.Due to highest water in this five samples Content is only 25wt%, therefore can conclude that phase is reversed hexagonal.The result of this and polarisation photo is consistent.Sample F6In addition to There are weaker 100, outside 110,200 three peaks, also other several miscellaneous peaks show that the liquid crystalline sample belongs to mixed phase, internal It is partly Hexagonal packing to only have in network structure.Sample F3And F4The first scattering peak on there are one faint acromion, it may be possible to it is few Other of amount mutually adulterate, this doping may be mutually lamellar phase.
φLIt is the volume fraction of surfactant hydrophobic part；φoIt is the volume fraction of oil phase.
vLRepresent the volume of surfactant hydrophobic tail.
dH=α -2dW (3)
SAXS parameters in analytical table 1 are it is found that for F1→F3Sample, with the increase of oil content, each surfactant The interfacial area a of moleculesIt is sequentially reduced.Show to accumulate between surfactant molecule finer and close, structure is more stablized, can Can be the polar hydroxyl groups solubilising of oleic acid and PEG caused by interfacial film.The hydrophobic radius d of rod-shaped micelleHIt gradually increases, thus it is speculated that oil phase Solubilising is between hydrophobic palisade layer so that hydrophobic tail is more unfolded.Sample F2And F3Radius of water droplet dwBoth less than oil content compared with Low F1Sample, the reason of causing this phenomenon may there are two types of, first, because of the reduction of water content itself, second is that because solubilising PEG 400 and tea polyphenols in kernel make the hydrophilic head generation of SL partially dehydrated since the effect of hydrogen bond is combined with water.Sample Product F2And F3Radius of water droplet dwVery close to, it may be possible to the hydrogen bond action in water core is mainly the reason that tea polyphenols cause.Fixed water Content, the F successively increased with surface-active contents4, F2And F5Sample, their dHIt is sequentially reduced, it may be possible to surface-active The winding degree of agent hydrophobic tail increases caused by the reduction with oil content.The a of samplesAnd dwDo not have with the increase of surface-active contents Have and show regular variation, this may be with F4Other adulterated in sample are mutually related.F6Reversed hexagonal has not been main in sample Phase is wanted, therefore its SAXS parameter can not be calculated.
The TP in Fig. 4 is the infrared spectrum of tea polyphenols as shown in Figure 4, it is possible to find itself and the infrared spectrum for carrying medicine liquid crystalline sample It is significantly different.Research is the vibration of all functional groups in sample in infrared spectrum.The infrared spectrum of liquid crystal is shown and original The relevant absorption peak of material function group, this shows not chemically reacting between liquid crystal each component.Small content groups in liquid crystal The absorption peak divided is covered by the characteristic absorption peak of lecithin.3300-3400cm-1The absorption peak at place is due to water, 400 Hes of PEG The stretching vibration of oleic acid-OH, this is related with the HYDROGEN BOND INTENSITY of hydrophilic area.The v of stability at lower frequenciesOHReacted it is stronger or more from The hydrogen bond of hair.F1, F2, F5And F6The v of sampleOHAll at 3376 frequencies.F3And F4The v of sampleOHRespectively in lower 3339 He At 3333 frequencies, this shows that high oil content is conducive to the formation of hydrogen bond, and the structure of sample is more stablized.This is with them in table 1 In smaller asIt is consistent.Liquid crystalline sample is in 2920cm-1The absorption peak at place is due to CH on lecithin and oleic acid alkyl chain3Function The stretching vibration of group C-H.In~2848cm-1(stretching vibration of C-H on alkyl chain) ,~1735cm-1(- the CO on carbonyl shakes It is dynamic) and~1461cm-1Absorption peak at (bending vibration of C-H on alkyl chain) is due to lecithin, and PEG 400 and oleic acid are deposited .~721cm-1It the peak at place may be related with the swing of CH on alkyl chain.In 1228cm-1The absorption band at place, is attributed to lecithin PO in molecule2 -Extensional motion.
As shown in Figure 5, the release time of tea polyphenols, it is more than hour all to reach 130 in liquid crystalline sample, and height is maintained to release The time for putting rate, it is more than hour to reach 40-60, illustrates that liquid crystalline sample has preferable sustained release performance to tea polyphenols.It is first 20 small When, all liquid crystalline samples show the quick release to poor polyphenol, wherein with F6Sample is the most prominent.Faster release with originally The concentration of drug is related.It can also clearly be found from figure, tea polyphenols show accumulative release in the liquid crystal of different component The difference of rate.Tea polyphenols in water core will be discharged into release medium, initially pass through fat hydrosphere facial mask, then by close by hydrophobic tail Collect the palisade layer of winding.HIISample F2, F3And F4Largest cumulative release rate all 60% or so, show these three samples to tea The slow release effect of polyphenol is more preferable.This smaller with three samplessIt is worth consistent.F5Sample possesses smaller asValue and release rate reaches It is that a best carrier-holding liquid crystal structure maintains higher release while stabilization in this 6 samples to 70% Put rate.For mixed phase F6, since release profiles it can be found that phenomenon of burst release having, and released after 80 hours Put rate increase, thus it is speculated that be because structural damage has occurred in the long-term soaking process of dissolution medium in structure.
The release of tea polyphenols at any time is fitted with first order kinetics.Equation is as follows：
Wherein, K is kinetic constant；N is release index, the releasing mechanism for characterizing drug；Mt/M∞It is drug in t The release percentage at moment.Fit indices R2It is listed in Table 1 below.
Sample F1, F3, F4And F5Fit indices R2All 0.99 or more, sample F2Fit indices R20.98 or more, Illustrate that the diffusion of drug belongs to concentration control.Sample F6Fit indices R2Only 0.96 or more, illustrate tea polyphenols releasing wherein It puts and also has carrier effect other than the diffusion for being related to concentration control, such as swelling and course of dissolution.
It summarizes：
The application is prepared for the sample of reversed hexagonal liquid crystal structure, when oil content is higher, is conducive to hydrogen between component molecular The formation of key and the stabilization of liquid crystal structure, generally finer and close oil-water interfaces layer can make the accumulative release rate of drug reduce.It releases It puts dynamics and shows that the release in vitro of drug belongs to concentration control.By this research, we can further infer that structural property The pharmaceutical carrier having both with release performance can be regulated and controled by the component of carrier to obtain.
The foregoing is merely the preferred embodiments of the application, are not intended to limit this application, for the skill of this field For art personnel, the application can have various modifications and variations.Within the spirit and principles of this application, any made by repair Change, equivalent replacement, improvement etc., should be included within the protection domain of the application.

Claims (10)

1. a kind of lecithin aliphatic radical reversed hexagonal liquid crystal medicament of tea polyphenols, it is characterised in that：By tea polyphenols, lecithin, oleic acid, PEG 400 and H2O is formed；Each section forms：The mass ratio of tea polyphenols in a medicament is 1%；Remaining as carrier；Lecithin, Oleic acid, PEG 400 and H2O forms carrier；Lecithin is 49.5-70 parts in carrier, and oleic acid is 2-11 parts, and PEG 400 is 2-11 Part and H2O is 9-47.5 parts.
2. a kind of lecithin aliphatic radical reversed hexagonal liquid crystal medicament of tea polyphenols according to claim 1, it is characterised in that：Lecithin Fat is surfactant.
3. a kind of lecithin aliphatic radical reversed hexagonal liquid crystal medicament of tea polyphenols according to claim 1, it is characterised in that：Oleic acid Oil phase is formed with PEG 400.
4. a kind of lecithin aliphatic radical reversed hexagonal liquid crystal medicament of tea polyphenols according to claim 1, it is characterised in that：It is described The mass ratio of oleic acid and PEG 400 in oil phase is 5：5.
5. a kind of preparation method of the lecithin aliphatic radical reversed hexagonal liquid crystal medicament of tea polyphenols, it is characterised in that：The specific steps are：
1) oleic acid and PEG 400 are mixed and the colorimetric with plug is added with certain mass ratio as oil phase, lecithin and oil phase Guan Zhong is sufficiently stirred mixing in the water-bath of certain temperature；
2) tea polyphenols are added in the mixture obtained to step 1 and redistilled water is stirred evenly and is centrifuged repeatedly to drive gas away Bubble；
3) colorimetric cylinder that step 2 obtains is stood in water bath with thermostatic control and obtains medicament sample.
6. preparation method according to claim 5, it is characterised in that：The mass ratio of lecithin and oil phase in the step 1) It is 61：21~77：5.
7. preparation method according to claim 5, it is characterised in that：The temperature of the step 1) water-bath is 60-70 DEG C.
8. preparation method according to claim 5, it is characterised in that：In the step 2) redistilled water and lecithin Than being 49：47.5~69：9.
9. preparation method according to claim 5, it is characterised in that：The temperature of water-bath in the step 3 is 37 ± 0.1 ℃。
10. a kind of lecithin aliphatic radical reversed hexagonal liquid crystal medicament of tea polyphenols according to claim 5, it is characterised in that：Institute Stating time that reaching in step 3 balances each other is more than or equal to one week.
CN201810124148.4A 2018-02-07 2018-02-07 A kind of the lecithin aliphatic radical reversed hexagonal liquid crystal medicament and preparation method of tea polyphenols Pending CN108309954A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810124148.4A CN108309954A (en) 2018-02-07 2018-02-07 A kind of the lecithin aliphatic radical reversed hexagonal liquid crystal medicament and preparation method of tea polyphenols

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810124148.4A CN108309954A (en) 2018-02-07 2018-02-07 A kind of the lecithin aliphatic radical reversed hexagonal liquid crystal medicament and preparation method of tea polyphenols

Publications (1)

Publication Number Publication Date
CN108309954A true CN108309954A (en) 2018-07-24

Family

ID=62903214

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810124148.4A Pending CN108309954A (en) 2018-02-07 2018-02-07 A kind of the lecithin aliphatic radical reversed hexagonal liquid crystal medicament and preparation method of tea polyphenols

Country Status (1)

Country Link
CN (1) CN108309954A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109125508A (en) * 2018-11-01 2019-01-04 山东师范大学 A kind of tea polyphenols lysotropic liquid crystal dispersion and preparation method
CN109528656A (en) * 2018-12-28 2019-03-29 山东师范大学 There is sustained release and the pharmaceutical carrier of protective effect and its preparation method and application to curcumin
CN113842370A (en) * 2021-11-01 2021-12-28 石家庄四药有限公司 Arbidol hydrochloride tablet and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107582515A (en) * 2017-09-22 2018-01-16 山东师范大学 A kind of pharmaceutical carrier and preparation method of lecithin aliphatic radical load dihydromyricetin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107582515A (en) * 2017-09-22 2018-01-16 山东师范大学 A kind of pharmaceutical carrier and preparation method of lecithin aliphatic radical load dihydromyricetin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
陈玉林等: "溶致液晶作为药物载体的研究进展", 《中国新药杂志》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109125508A (en) * 2018-11-01 2019-01-04 山东师范大学 A kind of tea polyphenols lysotropic liquid crystal dispersion and preparation method
CN109528656A (en) * 2018-12-28 2019-03-29 山东师范大学 There is sustained release and the pharmaceutical carrier of protective effect and its preparation method and application to curcumin
CN109528656B (en) * 2018-12-28 2020-11-20 山东师范大学 Drug carrier with slow release and protection effects on curcumin, and preparation method and application thereof
CN113842370A (en) * 2021-11-01 2021-12-28 石家庄四药有限公司 Arbidol hydrochloride tablet and preparation method thereof

Similar Documents

Publication Publication Date Title
CN108309954A (en) A kind of the lecithin aliphatic radical reversed hexagonal liquid crystal medicament and preparation method of tea polyphenols
US9034087B2 (en) Ink formulation and manufacture thereof
US11839590B2 (en) Flurbiprofen axetil emulsion for injection and preparation method thereof
CN104622710A (en) Preparation and application of salicylic acid and chitosan compound composition
CN111643452A (en) Oxyresveratrol nanoemulsion as well as preparation method and application thereof
CN106214565A (en) Anti crease and anti senile prepared old hyaluronate sodium essence of food grade and preparation method thereof
CN116850073A (en) Active substance eutectic solvent liposome face cream and preparation method thereof
CN101618016B (en) Method for preparing W/O/W type compound emulsion embedding chlorogenic acid, product and application of W/O/W type compound emulsion
CN105581919B (en) Ferulic acid phosphatide complexes and its purposes in preparing the cosmetics with white-skinned face function
CN108113964A (en) Based on constructing for 80 bio-compatible microemulsions of Tween, the release in vitro of apiolin and antioxygenic property research are carried
CN109414390A (en) Skin preparations for extenal use
TWI658840B (en) Emulsified liposome composition and method for making the same
CN114588108B (en) Oil-soluble solution containing insect repellent and preparation method and application thereof
CN104523591B (en) Without sensitization, painless propofol fat micro emulsion frozen preparation formula and preparation method
CN116672277A (en) Sun-screening composition and preparation method and application thereof
CN109549926A (en) A kind of preparation method of pH sensitive liposome
CN109364029A (en) A kind of resveratrol microballoon and preparation method thereof
CN108785682A (en) A kind of lipid carrier and preparation method thereof, application to low aqueous solubility Polyphenols drug with slow releasing function
Ortan et al. Topical delivery system of liposomally encapsulated volatile oil of anethum graveolens
CN107397688A (en) A kind of water-in-oil type cosmetic and preparation method containing melanin
CN109125267A (en) A kind of pair of curcumin has the preparation method and release in vitro performance of the lysotropic liquid crystal carrier of protective effect
CN104274337B (en) A kind of Liquid Crystalline Biomacromolecules is as skin care item moisturizing ingredient and preparation method thereof
CN109528656A (en) There is sustained release and the pharmaceutical carrier of protective effect and its preparation method and application to curcumin
CN108938456A (en) A kind of composition and preparation method and application
Kumar et al. Citric acid topical lecithin Pluronic organogel used as anti-skin ageing: development and characterization

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180724